scPharmaceuticals (NASDAQ:SCPH) Receives “Buy” Rating from HC Wainwright

HC Wainwright restated their buy rating on shares of scPharmaceuticals (NASDAQ:SCPHFree Report) in a report issued on Wednesday, Benzinga reports. They currently have a $18.00 target price on the stock. HC Wainwright also issued estimates for scPharmaceuticals’ Q2 2024 earnings at ($0.42) EPS, Q3 2024 earnings at ($0.40) EPS, Q4 2024 earnings at ($0.32) EPS, FY2024 earnings at ($1.50) EPS, FY2025 earnings at ($0.53) EPS, FY2026 earnings at $0.65 EPS, FY2027 earnings at $1.95 EPS and FY2028 earnings at $3.46 EPS.

scPharmaceuticals Trading Down 1.6 %

SCPH opened at $4.75 on Wednesday. The firm has a market capitalization of $171.24 million, a P/E ratio of -3.21 and a beta of 0.09. The firm’s 50 day moving average is $4.88 and its 200-day moving average is $5.38. The company has a quick ratio of 6.40, a current ratio of 6.21 and a debt-to-equity ratio of 1.60. scPharmaceuticals has a 52-week low of $4.01 and a 52-week high of $11.75.

scPharmaceuticals (NASDAQ:SCPHGet Free Report) last issued its quarterly earnings data on Tuesday, May 14th. The company reported ($0.36) EPS for the quarter, topping analysts’ consensus estimates of ($0.45) by $0.09. scPharmaceuticals had a negative net margin of 327.29% and a negative return on equity of 132.39%. The firm had revenue of $6.10 million for the quarter, compared to analyst estimates of $6.50 million. During the same quarter in the previous year, the business posted ($0.30) EPS. Analysts expect that scPharmaceuticals will post -1.46 EPS for the current fiscal year.

Institutional Trading of scPharmaceuticals

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Raymond James & Associates increased its position in shares of scPharmaceuticals by 5.7% in the 3rd quarter. Raymond James & Associates now owns 81,672 shares of the company’s stock worth $582,000 after purchasing an additional 4,420 shares during the last quarter. Rice Hall James & Associates LLC lifted its holdings in scPharmaceuticals by 9.1% during the 3rd quarter. Rice Hall James & Associates LLC now owns 87,071 shares of the company’s stock worth $620,000 after buying an additional 7,241 shares during the last quarter. AIGH Capital Management LLC increased its holdings in shares of scPharmaceuticals by 7.6% in the 3rd quarter. AIGH Capital Management LLC now owns 2,207,009 shares of the company’s stock valued at $15,714,000 after acquiring an additional 155,204 shares during the last quarter. Tejara Capital Ltd acquired a new stake in shares of scPharmaceuticals during the 3rd quarter valued at approximately $722,000. Finally, Rubric Capital Management LP lifted its stake in scPharmaceuticals by 234.3% during the third quarter. Rubric Capital Management LP now owns 2,713,287 shares of the company’s stock worth $19,319,000 after purchasing an additional 1,901,770 shares during the last quarter. Institutional investors own 89.52% of the company’s stock.

scPharmaceuticals Company Profile

(Get Free Report)

scPharmaceuticals Inc, a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. Its lead product candidate is FUROSCIX that consists of formulation of furosemide, which is delivered through an on-body infusor for treatment of congestion due to fluid overload in adults with chronic heart failure and kidney disease, as well as consists of subcutaneous loop diuretic that delivers IV equivalent diuresis at home; and FUROSCIX On-Body Infusor, a drug-device combination product consisting of FUROSCIX.

Featured Articles

Receive News & Ratings for scPharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for scPharmaceuticals and related companies with's FREE daily email newsletter.